Global Precision Cardiology Market Research Report: Trends, Forecast & Opportunities (2026-2032)

Global Precision Cardiology Market Report Key Takeaways

The global precision cardiology market was valued at USD 5.31 billion in 2025 and is projected to grow from USD 6.14 billion in 2026 to USD 10.13 billion by 2032.

The industry is expected to exhibit a CAGR of 8.70% during 2026–2032.

North America dominates the market, accounting for the largest regional share of 42% in 2026.

Blood leads the sample type dimension with a 70% share in 2026.

Next-Generation Sequencing (NGS) holds a 48% technology share as the dominant platform in 2026.

The market is moderately consolidated, with the top players collectively commanding a combined share of 55%.

Global Precision Cardiology Market Size and Outlook

The global precision cardiology market is set to expand at a CAGR of 8.70% during 2026–2032. Precision cardiology integrates genomic profiling, cardiovascular biomarker testing, and next-generation sequencing (NGS) technologies to deliver individualized diagnosis, genetic risk stratification, and targeted therapeutic management of cardiovascular diseases. Primary end-users span hospitals, cardiac care centers, clinical diagnostic laboratories, contract research organizations, and pharmaceutical companies engaged in personalized cardiovascular medicine development.

The market's structural importance is reinforced by cardiovascular disease's position as the leading cause of global mortality, with the Global Burden of Disease study published in JACC in September 2025 confirming 19.2 million cardiovascular deaths in 2023 and 626 million prevalent cases globally, establishing the scale of the patient population that requires precision-based cardiac diagnostics and individually tailored therapeutic intervention.

Government-backed precision medicine programs are directly strengthening institutional demand for genomic cardiovascular diagnostics and blood-based biomarker analysis platforms across North America. The National Institutes of Health (NIH) All of Us Research Program, the largest longitudinal precision medicine initiative in United States history, continues generating cardiovascular genomic datasets that support NGS-based cardiac genetic risk scoring and polygenic risk stratification for ischemic heart disease, inherited cardiomyopathy, and hereditary arrhythmia syndromes.

Additionally, the US Food and Drug Administration has clarified regulatory pathways for AI-assisted clinical decision-support software and companion diagnostic platforms through updated 2026 guidance, reducing commercialization barriers and encouraging broader integration of precision cardiology tools into standard clinical cardiology workflows across hospital networks and outpatient settings.

Industrial adoption has accelerated as leading life science and molecular diagnostics companies expand their precision cardiovascular medicine portfolios to address rising clinical demand for high-throughput genetic testing and cardiac biomarker quantification. For instance, in December 2025, Abbott Laboratories received U.S. FDA approval for its Volt™ Pulsed Field Ablation (PFA) System, an all-in-one precision cardiac ablation platform designed to treat patients with atrial fibrillation.

The system was validated through a clinical trial involving 392 patients across 40 centers in the United States, Europe, Canada, and Australia, with commercial rollout initiated across both the United States and the European Union, where the device had already received CE Mark approval in March 2025. Also, Thermo Fisher Scientific and Illumina continue expanding NGS-based cardiac gene panel platforms that support inherited cardiovascular disease diagnosis and pharmacogenomic-guided therapy selection across clinical and research environments.

Looking ahead, the global precision cardiology market is expected to sustain its growth trajectory, expanding from USD 6.14 billion in 2026 to USD 10.13 billion by 2032, as healthcare systems progressively shift from conventional symptom-driven treatment toward proactive, genomics-informed cardiovascular patient management. The European Society of Cardiology’s European Journal of Preventive Cardiology projects global cardiovascular disease prevalence to increase by 90% between 2025 and 2050, with crude cardiovascular mortality rising from 20.5 million in 2025 to 35.6 million by 2050.

This trajectory structurally reinforces long-term demand for scalable precision cardiac diagnostics, particularly blood-based biomarker assay platforms and NGS cardiac sequencing panels capable of enabling early cardiovascular risk identification, inherited disease diagnosis, and longitudinal disease monitoring across diverse patient populations worldwide.

Global Precision Cardiology Market Key Indicators

• According to the Global Burden of Cardiovascular Diseases and Risk Factors study published in the Journal of the American College of Cardiology (JACC) on 24 September 2025 cardiovascular diseases caused 19.2 million deaths globally in 2023 up from 13.1 million in 1990 while prevalent cases more than doubled to 626 million, representing one in three deaths worldwide; this escalating patient burden establishes an expanding and structurally non-discretionary demand base for precision cardiovascular diagnostics, genomic risk stratification, and blood-based biomarker monitoring platforms.
• The American Heart Association's Direct-to-Consumer Genetic Testing for Cardiovascular Disease Scientific Statement, approved by the AHA Science Advisory and Coordinating Committee on 26 November 2024 and the Executive Committee on 16 January 2025 formally recognized the growing role of consumer and clinical genetic testing in cardiovascular risk identification, reinforcing North America's institutional and regulatory framework for genomic cardiology adoption; the AHA's scientific endorsement of cardiovascular genetic screening accelerates clinical uptake of NGS-based testing and blood-sample biomarker profiling across US hospital networks, cardiology practices, and diagnostic laboratories, underpinning North America's dominant regional position in the global precision cardiology market.
• A review published in Clinical Chemistry and Laboratory Medicine (CCLM) in June 2025 by the Italian Study Group on Cardiac Biomarkers confirmed that high-sensitivity cardiac troponin assays, which detect troponin concentrations in blood samples from more than 50% of healthy individuals, are now mandated by international guidelines for acute myocardial infarction diagnosis and risk stratification; the clinical embedding of these blood-based precision biomarkers into standard emergency and outpatient cardiology workflows establishes blood as the dominant sample type in precision cardiology, directly reinforcing demand.

Global Precision Cardiology Market Scope

Global Precision Cardiology Market Growth Drivers

Rising Clinical Mandate for Genomic Risk Stratification in Inherited Cardiovascular Disease

The increasing clinical recognition of inherited cardiovascular diseases as a primary driver of sudden cardiac death and heart failure is creating a structurally expanding demand base for genomic diagnostic platforms across precision cardiology.

According to the 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy, published jointly in the Journal of the American College of Cardiology , genetic testing is now a Class I recommended standard of care for all patients diagnosed with hypertrophic cardiomyopathy (HCM) the most common inherited cardiac disease, affecting approximately one in every 500 adults globally.

The guideline further mandates cascade genetic testing across first-degree family members upon identification of a pathogenic variant, multiplying the per-patient testing footprint and generating recurring, guideline-driven procurement demand for NGS-based cardiac gene panels, blood-based sample collection, and clinical bioinformatics platforms across hospital networks and specialized HCM centers.

This guideline-level mandate structurally transforms genetic cardiac testing from an elective clinical tool into a non-discretionary diagnostic requirement embedded within standard cardiology care pathways.

Additionally, the Japanese Circulation Society, the Japanese College of Cardiology, and the Japanese Society of Pediatric Cardiology jointly published the JCS/JCC/JSPCCS 2024 Guideline on Genetic Testing and Counseling in Cardiovascular Disease, formally integrating NGS-based multi-gene cardiovascular panel testing into Japanese clinical cardiology practice, covering inherited cardiomyopathies, channelopathies, and hereditary arrhythmia syndromes, reinforcing Japan as a structurally significant precision cardiology demand market within Asia-Pacific.

This creates a sustained, regulation-backed demand multiplier for precision cardiology diagnostic platforms, reinforcing the market's long-term structural growth trajectory globally.

Recent Trends

Accelerating Integration of AI-Driven Multi-Omics Platforms into Cardiovascular Precision Diagnostics

The most defining structural trend reshaping the global precision cardiology market is the convergence of artificial intelligence with multi-omics cardiovascular biomarker profiling, integrating genomic, proteomic, and blood-based cardiac biomarker data into unified computational diagnostic systems, shifting clinical cardiology from single-marker testing toward AI-enabled, multi-dimensional cardiovascular risk stratification at scale.

This transition is becoming increasingly visible in the United States, where the U.S. Food and Drug Administration had cleared more than 200 cardiology-specific AI algorithms by March 2026, making cardiovascular medicine one of the fastest-growing AI-integrated specialties globally. Industry tracking further indicates that the FDA was averaging nearly 200 cardiovascular AI-related approvals annually by 2025. Also, Anumana received FDA clearance for its ECG -AI™ Low Ejection Fraction algorithm, together, these developments are structurally embedding AI-powered cardiac biomarker analytics into reimbursable hospital cardiology workflows across North America.

As regulatory adoption strengthens in North America, European healthcare systems are increasingly focusing on clinical validation and real-world predictive performance of AI-enabled cardiovascular diagnostics during the European Society of Cardiology Congress in Madrid formally validated AI-driven multi-omics cardiovascular diagnostics as clinically deployable, with Oxford University researchers presenting late-breaking evidence that Caristo Diagnostics' CaRi-Heart® AI coronary inflammation biomarker tool outperforms blood-based high-sensitivity C-reactive protein (hsCRP) in predicting cardiac death.

Collectively, these developments indicate that the precision cardiology market is transitioning from an emerging genomics-focused niche into a clinically integrated, AI-enabled cardiovascular intelligence ecosystem.

Global Precision Cardiology Market Opportunities and Challenges

Low Cardiovascular Genetic Testing Uptake Creating Opportunity for Scalable, Low-Cost NGS-Based Precision Cardiology Platforms

Cardiovascular genomics sits at a paradox guideline-mandated, clinically validated, yet structurally underutilized at a scale that represents one of the most acute unmet needs in personalized cardiac care today. According to the 2026 American College of Cardiology Scientific Statement, only approximately 1% of patients with guideline-indicated inherited cardiovascular diseases receive appropriate NGS-based cardiac genetic testing in clinical practice, with 90–95% of high-risk genomic variant carriers remaining undiagnosed.

Reinforcing this concern, the American Heart Association’s November 2025 policy statement published in Circulation identified high testing costs, inconsistent insurance reimbursement, limited access to genetic counselors, and geographic healthcare inequality as the primary structural barriers restricting broader adoption of cardiovascular precision diagnostics, particularly across rural, lower-income, and underrepresented populations in North America, Asia-Pacific, and the GCC.

At the same time, this diagnostic under penetration is emerging as one of the largest long-term commercial opportunities within the precision cardiology market, particularly as sequencing economics continue to improve rapidly. For instance, In the GCC, Saudi Arabia's Ministry of Health awarded Genalive a joint venture of BGI Genomics the largest genetic testing tender in NUPCO's history in March 2025, covering 930,000 NGS-based genetic testing services across 83 public hospitals throughout the Kingdom under a three-year contract valued at USD 132 million .

Therefore, these developments indicate that the convergence of declining sequencing costs, expanding reimbursement discussions, and government-backed cardiovascular genomics programs is steadily transforming the precision cardiology testing gap into a structurally expanding global market opportunity.

Segmentation Analysis

Blood Leads as the Dominant Sample Type in Precision Cardiology

Blood leads the sample type dimension within the global precision cardiology market with a market share of 70% because it functions as the foundational data-generation layer powering every downstream component of the precision cardiology ecosystem. Blood-based NGS cardiac gene panels generate the inherited cardiovascular disease variant data that AI platforms consume to produce individualized therapy recommendations and genomic risk stratification outputs.

Simultaneously, blood-based cardiac biomarker assays including high-sensitivity cardiac troponin and circulating cell-free DNA deliver the real-time biological signals that remote monitoring and treatment recommendation systems depend on to detect disease progression and trigger precision therapeutic interventions.

In the United States, Tempus AI completed its USD 375 million acquisition of Ambry Genetics on 3 February 2025, explicitly targeting expansion into blood-based NGS cardiovascular genetic testing to feed its AI-driven precision cardiology platform. Reinforcing this, Illumina and MyOme announced a formal collaboration on 11 December 2025 to combine blood-based whole-genome sequencing with AI-integrated polygenic cardiovascular risk models specifically designed to identify individual cardiac disease susceptibility earlier than standard clinical calculators .

These converging investments across the United States and Europe confirm that blood's leadership within the precision cardiology market extends far beyond diagnostics reflecting its irreplaceable role as the biological data source activating the full precision cardiology value chain including AI cardiovascular risk stratification, personalized drug selection, inherited cardiac disease cascade screening, and population-level polygenic risk prevention. The sub-categories covered under the sample type dimension include:

• Blood
• Non-Blood
• Saliva
• Tissue Biopsies.

NGS Leads as the Dominant Technology in Precision Cardiology

Next-generation sequencing dominates the technology dimension of the global precision cardiology market with 48% market share of because it is the only platform capable of simultaneously interrogating hundreds of cardiovascular disease-associated genes covering inherited cardiomyopathies, channelopathies, hereditary arrhythmia syndromes, and familial hypercholesterolemia from a single blood sample, delivering diagnostic yields that substantially exceed both traditional Sanger sequencing and chromosomal microarray platforms.

Globally, leading cardiovascular clinical authorities are embedding NGS into formal precision cardiology frameworks across multiple regions. In Europe, the ESC Council on Cardiovascular Genomics published a Clinical Consensus Statement in the European Heart Journal formally mandating the integration of NGS-based genetic testing into routine cardiomyopathy diagnostic pathways across all ESC member countries.

In the United States, the AHA's November 2025 Policy Statement on Genetic and Genomic Testing in Cardiovascular Disease formally called for system-level embedding of NGS-based cardiovascular genetic testing into routine clinical cardiology workflows across US hospital networks, directly expanding institutional NGS procurement demand.

These concurrent European and North American clinical authority mandates confirm that NGS technology is transitioning from specialist genomics into a non-discretionary standard embedded across the full precision cardiology value chain, powering inherited disease diagnosis, AI cardiovascular risk stratification, polygenic risk prevention, and pharmacogenomic therapy guidance simultaneously.

As multi-society guidelines continue mandating NGS-based cardiovascular testing globally, the technology segment is structurally positioned to consolidate and extend its dominance throughout the forecast period. By technology dimension, the market is further divided into the following sub-categories:

• Next-Generation Sequencing (NGS)
• Sanger Sequencing
• Polymerase Chain Reaction (PCR)
• Microarray Technology

Global Precision Cardiology Market Geographical Analysis

North America commands the leading position in the global precision cardiology market, accounting for 45% of total market share, underpinned by the world's highest concentration of cardiovascular disease burden, clinical genomics infrastructure, and institutional precision medicine investment. The NHLBI maintained a USD 3.98 billion annual budget in FY2025, explicitly directing precision medicine and data science as strategic priorities through its TOPMed cardiovascular whole-genome sequencing program . This sustained federal funding creates the genomic reference infrastructure, clinical research capacity, and institutional adoption pathways that structurally differentiate North America from every other region globally.

North America hosts the world's densest concentration of precision cardiology technology innovators, directly reinforcing commercial dominance. 61% of all FDA AI-enabled cardiovascular device submissions originated from North American companies. Input Form companies headquartered in the region, including Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Edwards Lifesciences Corporation, Illumina Inc., and Thermo Fisher Scientific Inc., collectively span the full precision cardiology value chain from NGS cardiac gene panels through AI cardiovascular diagnostic platforms.

The AHA's projection that 184 million Americans will be affected by cardiovascular disease by 2050 will sustain continuous institutional demand acceleration across genomic medicine programs, AI diagnostic platforms, and personalized cardiovascular therapy systems throughout the forecast period.

Global Precision Cardiology Market Competitive Analysis

The global precision cardiology market is moderately consolidated, with companies operating across five distinct competitive tiers, NGS sequencing platforms, cardiovascular biomarker diagnostics, cardiac monitoring and electrophysiology, AI-driven genomic software, and centralized laboratory services. The top players collectively command a dominant combined share, with Illumina, Thermo Fisher Scientific, Abbott Laboratories, and Roche Diagnostics anchoring competitive strength across the genomics infrastructure and cardiovascular biomarker diagnostics dimensions respectively with a combined share of 55%.

Major Companies in Precision Cardiology Market

Illumina

Thermo Fisher Scientific

Abbott Laboratories

Roche Diagnostics

Medtronic

Quest Diagnostics

Laboratory Corporation (LabCorp)

Siemens Healthineers

iRhythm Technologies

Pacific Biosciences (PacBio)

Oxford Nanopore Technologies

BGI Genomics / MGI Tech

QIAGEN

Agilent Technologies

Tempus

SOPHiA GENETICS

GeneDx

Invitae

Mayo Clinic Laboratories

BioTelemetry (Philips)

AliveCor

Cardiologs (Philips)

Others

Global Precision Cardiology Industry News and Recent Developments

June 2025: Eli Lilly Acquires Verve Therapeutics to Advance Precision Gene Editing for Cardiovascular Disease

In June 2025, Eli Lilly and Company announced a definitive agreement to acquire Verve Therapeutics, a Boston-based clinical-stage company developing in vivo gene editing medicines for cardiovascular disease, for approximately USD 1 billion at closing, with total potential consideration of up to USD 1.3 billion including contingent value rights. Verve's lead program, VERVE-102, is a first-in-class in vivo base editing medicine designed to permanently turn off the PCSK9 gene in the liver, reducing low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia and established atherosclerotic cardiovascular disease. VERVE-102 received FDA Fast Track designation in April 2025 and was actively enrolled in a Phase Ib clinical trial at the time of acquisition. The transaction closed in Q3 2025, adding Verve's additional pipeline assets targeting ANGPTL3 and LPA genes to Lilly's precision cardiovascular therapeutics portfolio

Impact analysis: The acquisition repositions the precision cardiology market's personalized therapy dimension shifting its commercial trajectory from chronic pharmacological management toward single-dose, gene-level cardiovascular disease resolution. It establishes a new competitive benchmark for precision cardiovascular drug development, increasing entry barriers for companies without in vivo gene editing capabilities and accelerating demand for NGS-based cardiovascular genetic testing as a prerequisite companion diagnostic for VERVE-102 patient selection globally.

September 2025: Quest Diagnostics Launches Advanced Pharmacogenomics Service Covering Cardiology Drug-Gene Interactions

In September 2025, Quest Diagnostics (NYSE: DGX) formally launched an advanced pharmacogenomic (PGx) laboratory test service analyzing 17 genes and four HLA alleles to deliver genotype-based medication guidance across multiple clinical specialties, explicitly including cardiology alongside psychiatry, neurology, and oncology. The service integrates Quest's NGS-based genotyping infrastructure with Coriell Life Sciences' GeneDose LIVE clinical decision support platform, providing cardiologists with real-time, evidence-based gene-drug interaction analysis for cardiovascular medication selection and dosing optimization at the point of care. The offering covers pharmacogenomic profiles relevant to cardiovascular drug classes including antiplatelets, antiarrhythmics, anticoagulants, and lipid-lowering therapies

Impact analysis: Quest Diagnostics' PGx launch directly operationalizes pharmacogenomic-guided cardiovascular precision therapy at population scale through its established national laboratory network, embedding NGS-based cardiovascular drug-gene profiling into routine clinical cardiology workflows across US hospital systems. This deployment expands the precision cardiology market's addressable revenue base beyond genetic diagnosis into pharmacogenomic treatment optimization, accelerating the convergence of genomics, AI decision support, and personalized cardiovascular drug selection within the broader precision cardiology ecosystem.

April 2025: SOPHiA GENETICS Partners with Precision for Medicine to Expand AI-Driven Multimodal Cardiovascular Biomarker Discovery Globally

In April 2025, SOPHiA GENETICS (NASDAQ: SOPH) and Precision for Medicine — a leading drug development and commercialization services provider — announced a strategic partnership to integrate the SOPHiA DDM™ Platform into Precision for Medicine's biomarker discovery and clinical trial services, covering genomic, radiomic, and clinical multimodal data analysis across precision medicine applications including cardiovascular genetic disorders. Through the partnership, Precision for Medicine will deploy SOPHiA DDM™ Clinical Trial Assays and AI-driven algorithms to accelerate cardiovascular patient stratification, biomarker discovery, and clinical trial design optimization for biopharma clients. As of March 2025, SOPHiA's DDM platform had analyzed the genomic profiles of more than two million patients across 800 healthcare institutions in 72 countries, establishing it as the world's largest AI-driven multimodal genomic analytics network deployed in active clinical and research settings

Impact Analysis: The SOPHiA GENETICS–Precision for Medicine partnership extends AI-driven cardiovascular genomic biomarker discovery from isolated research programs into a structured commercial biopharma clinical trial services infrastructure — operationalizing multimodal cardiovascular precision diagnostics at population scale across 72 countries. It establishes SOPHiA's DDM platform as the competitive standard for AI-integrated cardiovascular genomic patient stratification in clinical trials, directly increasing demand for NGS-based cardiovascular biomarker profiling and AI-driven precision cardiology analytics platforms across the global precision cardiology market.

September 2025: Roche Announces CE Mark Approval and Global TSIX Study Results for Sixth-Generation High-Sensitivity Troponin T Test

In September 2025, Roche announced primary results from its landmark TSIX Study Program evaluating the Elecsys® Troponin T hs Gen 6 its sixth-generation high-sensitivity cardiac troponin T blood-based precision diagnostic assay, presented simultaneously at the European Society of Cardiology Congress 2025 and the European Society for Emergency Medicine Congress 2025 in Vienna. The TSIX program enrolled over 13,000 participants across 50 clinical sites spanning the United States, China, Japan, and the European Union, the largest global clinical study program conducted for troponin testing in cardiovascular precision diagnostics history. The PERFORM-TSIX prospective cohort component enrolled 5,631 patients presenting with acute coronary syndrome symptoms, with results confirming the Elecsys® Troponin T hs Gen 6 test's ability to identify acute myocardial infarction with high diagnostic precision, establishing sex-specific upper reference limits of 18 ng/L for females and 32 ng/L for males, meeting International Federation of Clinical Chemistry and Laboratory Medicine benchmarks. The test received CE Mark approval and is deployable across Roche's installed base of over 90,000 serum work area systems worldwide (

Impact Analysis: The Elecsys® Troponin T hs Gen 6 CE Mark approval and TSIX program results directly expand the addressable blood-based cardiovascular biomarker precision diagnostics market by establishing a new generation sex-specific diagnostic standard for acute myocardial infarction detection across emergency cardiology settings globally. Roche's deployment-ready infrastructure across 90,000 installed laboratory systems ensures immediate large-scale commercial penetration, raising competitive barriers for legacy troponin assay platforms and accelerating the global transition to next-generation blood-based precision cardiovascular biomarker testing within the broader precision cardiology market.